自拟益气养阴汤联合耳针治疗2型糖尿病胰岛素抵抗的临床观察

Clinical Observation of Self-made Yiqi Yangyin Decoction Combined with Auricular Acupuncture on Type 2 Diabetes Insulin Resistance

目的观察自拟益气养阴汤联合耳针治疗2型糖尿病胰岛素抵抗临床疗效。方法选取2型糖尿病胰岛素抵抗患者64例,随机分为观察组(自拟益气养阴汤加耳针埋穴)和对照组(口服二甲双胍片),各32例。治疗1个疗程(3个月)后观察两组临床疗效、治疗前后空腹血糖(FPG)、餐后2 h血糖(2h PG)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、总胆固醇(TC)、甘油三酯(TG)、糖化血红蛋白(Hb A1c)、高密度脂蛋白-胆固醇(HDL-C)、低密度脂蛋白-胆固醇(LDL-C)。结果观察组总有效率96.9%,高于对照组的84.4%,差异有统计学意义(P<0.05)。两组治疗后相关指标变化较治疗前比较,差异均有统计学意义(P<0.05或P<0.01);治疗后观察组FPG、2h PG、FINS、Hb A1c、TG、HDL-C、LDL-C与对照组比较,差异均有统计学意义(P<0.05或P<0.01)。结论自拟益气养阴汤联合耳针可能通过调节糖脂代谢而起到治疗2型糖尿病胰岛素抵抗的作用,且优于单纯应用二甲双胍片组,值得临床推广应用。

Objective To observe the clinical efficacy of Yiqi Yangyin decoction combined with auricular acupuncture on type 2 diabetes insulin resistance. Methods Sixty-four cases of type 2 diabetic patients with insulin resistance were randomly divided into the observation group （Yiqi Yangyin decoction, acupuncture buried points） and the control group （oral metformin tablets）, 32 cases in each group. The clinical efficacy of the two groups, fasting plasma glucose （FPG）, postprandial 2h plasma glucose （2hPG）, fasting insulin （FINS）, insulin resistance index （HOMA-IR）, total cholesterol （TC）, triglyceride （TG）, glycosylated hemoglobin （HbA1c）, high density lipoprotein cholesterol （HDL-C）, low density lipoprotein cholesterol （LDL-C） were observed after one course of treatment （3 months）. Results The total effective rate of the observation group was 96.9%, higher than that of the control group （84.4%）, the difference was statistically significant （P〈0.05）. The related indicators before and after treatment were statistically significant （P〈0.05 or P〈0.01）. Compared with the observation group, the FPG, 2hPG, FINS, HbA1c, TG, HDL-C, LDL-C in observation group were statistically significant （P〈0.05 or P〈0.01）. Conclusion Yiqi Yangyin decoction combined with auricular acupuncture may treat insulin resistance in type 2 diabetes by regulating glucose and lipid metabolism, and is better than the simple application of metformin tablets group, worthy of clinical application.